Daiken Medical Co., Ltd. (TYO:7775)
Japan · Delayed Price · Currency is JPY 424.00
0.00 (0.00%)
Sep 15, 2026, 11:02 AM JST
Daiken Medical Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 12,181 | 12,870 | 14,077 | 15,944 | 13,818 | 14,652 | |
Market Cap Growth | -8.62% | -8.57% | -11.71% | 15.38% | -5.69% | -16.26% |
Enterprise Value | 11,858 | 12,338 | 13,444 | 15,955 | 14,329 | 15,410 |
Last Close Price | 424.00 | 448.00 | 469.14 | 507.96 | 424.02 | 431.23 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 13.95 | 13.96 | 12.83 | 16.14 | 19.41 | 17.63 |
PS Ratio | 1.19 | 1.25 | 1.42 | 1.64 | 1.51 | 1.72 |
PB Ratio | 1.60 | 1.66 | 1.87 | 2.27 | 2.10 | 2.27 |
P/TBV Ratio | 1.60 | 1.66 | 1.88 | 2.28 | 2.10 | 2.28 |
P/FCF Ratio | 50.75 | 53.63 | 14.76 | 11.45 | 17.47 | 15.74 |
P/OCF Ratio | 21.48 | 22.70 | 12.57 | 10.25 | 13.97 | 12.93 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.16 | 1.20 | 1.35 | 1.64 | 1.57 | 1.80 |
EV/EBITDA Ratio | 8.05 | 8.04 | 7.71 | 9.63 | 10.84 | 10.52 |
EV/EBIT Ratio | 9.81 | 9.66 | 8.89 | 11.06 | 13.58 | 13.39 |
EV/FCF Ratio | 49.41 | 51.41 | 14.09 | 11.45 | 18.12 | 16.55 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.28 | 0.29 | 0.27 | 0.31 | 0.42 | 0.46 |
Debt / EBITDA Ratio | 1.43 | 1.48 | 1.18 | 1.29 | 2.08 | 2.00 |
Debt / FCF Ratio | - | 9.45 | 2.15 | 1.54 | 3.48 | 3.15 |
Net Debt / Equity Ratio | -0.04 | -0.07 | -0.13 | -0.08 | 0.04 | 0.06 |
Net Debt / EBITDA Ratio | -0.22 | -0.33 | -0.54 | -0.36 | 0.18 | 0.28 |
Net Debt / FCF Ratio | - | -2.12 | -0.99 | -0.43 | 0.30 | 0.45 |
Asset Turnover | 0.93 | 0.91 | 0.90 | 0.89 | 0.83 | 0.79 |
Inventory Turnover | 3.91 | 4.20 | 4.08 | 3.91 | 3.67 | 3.28 |
Quick Ratio | 1.83 | 1.97 | 1.93 | 1.56 | 1.50 | 1.57 |
Current Ratio | 2.54 | 2.58 | 2.47 | 2.02 | 1.97 | 2.09 |
Return on Equity (ROE) | 11.68% | 12.06% | 15.09% | 14.51% | 10.92% | 13.16% |
Return on Assets (ROA) | 6.87% | 7.08% | 8.52% | 8.19% | 6.01% | 6.64% |
Return on Invested Capital (ROIC) | 12.34% | 13.67% | 16.94% | 14.99% | 10.71% | 12.02% |
Return on Capital Employed (ROCE) | 14.40% | 14.80% | 18.10% | 18.80% | 13.80% | 14.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 7.17% | 7.16% | 7.79% | 6.20% | 5.15% | 5.67% |
FCF Yield | 1.97% | 1.86% | 6.78% | 8.74% | 5.72% | 6.35% |
Payout Ratio | - | 71.58% | 55.79% | 58.00% | 79.35% | 69.07% |